Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock (DISCO-SHOCK)

15 de agosto de 2026 atualizado por: tugba yesilyurt dogu, Istanbul University - Cerrahpasa

Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock: A Prospective Observational Cohort Study Evaluating Its Prevalence and Prognostic Value

In septic shock, restoring large-vessel (macrocirculatory) perfusion-reflected by a normal capillary refill time (CRT)-does not always mean that oxygen use at the tissue level has recovered. This mismatch, sometimes called loss of hemodynamic coherence, may be detectable by comparing CRT with the oxygen extraction ratio (O₂ER), a marker of how much oxygen the tissues are extracting from the blood. Patients whose CRT has normalized but whose O₂ER remains abnormal-either too high (suggesting oxygen delivery that is insufficient for demand) or too low (suggesting microcirculatory shunting)-are considered to have a "discordant" perfusion phenotype.

This prospective, single-center, observational cohort study aims to determine how often this CRT-O₂ER discordance occurs at the 6th hour of resuscitation in adult patients with septic shock, and whether it is associated with 28-day mortality. Approximately 100 consecutive adult patients diagnosed with septic shock (with pre-existing central venous and arterial catheters) will be followed. Clinical and laboratory measurements-including CRT, O₂ER, lactate, mottling score, and organ dysfunction scores-will be recorded at hours 0, 6, 12, and 24, with the main phenotype grouping performed at hour 6. The study is purely observational: CRT is a painless, non-invasive bedside measurement, and O₂ER is calculated from blood gas samples already drawn as part of routine care, so no additional interventions or blood draws are performed for research purposes.

Visão geral do estudo

Descrição detalhada

Background. In septic shock resuscitation, improvement of macrocirculatory targets such as blood pressure and capillary refill time (CRT) does not always reflect adequate oxygen utilization at the tissue level-a phenomenon described as loss of hemodynamic coherence. Although the ANDROMEDA-SHOCK trial highlighted CRT-targeted resuscitation, a subset of patients with a normalized CRT may still have impaired tissue oxygen balance. The oxygen extraction ratio (O₂ER) can deviate in two directions: a high O₂ER (>30%) suggests oxygen delivery that is insufficient for demand (e.g., low cardiac output, anemia), whereas a low O₂ER (<20%, with high central venous oxygen saturation) may reflect microcirculatory shunting and cytopathic hypoxia.

Primary aim. To determine the prevalence of the "discordant" phenotype-defined as a normalized CRT with an abnormal O₂ER at hour 6 of resuscitation-and to evaluate its association with 28-day mortality.

Secondary aims. (1) To examine the association between CRT/O₂ER-defined perfusion phenotypes and 28-day mortality, ICU and hospital length of stay, duration of mechanical ventilation, vasopressor-free days, and need for renal replacement therapy; (2) to validate the proposed O₂ER >30% threshold using ROC curve analysis and identify the optimal cut-off for mortality in this cohort; (3) to assess whether the discordant phenotype is an independent predictor of mortality after adjustment for age, APACHE II score, lactate, and noradrenaline dose using multivariable analysis; (4) to examine the relationship of discordance with complementary perfusion markers (lactate clearance, mottling score, venoarterial CO₂ difference).

Design and setting. Prospective, single-center, observational cohort study in an intensive care unit. Consecutive adult patients diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline will be enrolled. Time zero (Hour 0) is defined as the time of vasopressor (noradrenaline) initiation.

Measurements. While patients continue standard care, serial clinical and laboratory measurements are recorded at hours 0, 6, 12, and 24, and organ function at hour 72. CRT is measured in a standardized manner on the ventral surface of the distal phalanx of the right index finger after 10 seconds of firm pressure. O₂ER is calculated as (SaO₂ - ScvO₂) / SaO₂. At hour 6, CRT and blood gas sampling are performed simultaneously (within 15 minutes). Inter-rater reliability of CRT is assessed in the first 20-30 patients by two independent, blinded observers (ICC for continuous values; Cohen's kappa for the ≤3 s normal/abnormal classification).

Phenotype grouping (Hour 6). Group 1 - Concordant normal (CRT ≤3 s + O₂ER 20-30%); Group 2a - Discordant, high O₂ER (CRT ≤3 s + O₂ER >30%); Group 2b - Discordant, low O₂ER (CRT ≤3 s + O₂ER <20%); Group 3 - Concordant abnormal (CRT >3 s + abnormal O₂ER). The primary group of interest is the combined discordant phenotype (Group 2a + Group 2b).

Outcomes. Primary outcome: 28-day mortality (counted from Hour 0). Secondary outcomes: ICU and hospital length of stay, duration of mechanical ventilation, time to vasopressor weaning, vasopressor-free days, hour-72 organ function (SOFA-2, ongoing vasopressor/ventilation, lactate), and need for renal replacement therapy.

Sample size and statistics. A target of approximately 100 consecutive patients was chosen so that an expected discordance prevalence of ~30% can be estimated with a 95% confidence interval half-width of ±9%. Descriptive statistics, normality testing (Shapiro-Wilk), and appropriate parametric/non-parametric group comparisons will be used. The prevalence of the discordant phenotype will be reported with 95% CI. ROC analysis (with AUC) will evaluate the O₂ER threshold for mortality. Multivariable binary logistic regression (parsimonious model: phenotype, APACHE II, lactate; events-per-variable ≈12) will identify independent predictors of mortality, reported as odds ratios with 95% CI. Survival across phenotype groups will be estimated by Kaplan-Meier analysis and compared with the log-rank test. Statistical significance is set at p < 0.05.

Tipo de estudo

Observacional

Inscrição (Estimado)

100

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Tugba Yesilyurt Dogu, Intensive Medicine Care Fellow
  • Número de telefone: +9005535150847
  • E-mail: tugbaayesilyurt@gmail.com

Locais de estudo

      • Istanbul, Turquia (Türkiye)
        • Recrutamento
        • Başakşehir Çam and Sakura City Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

Consecutive adult patients (≥18 years) admitted to a single-center intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who already have a central venous catheter and an arterial line in place as part of their clinical care. Patients are enrolled from all admission sources (emergency department, ward, operating room, or external referral) and followed prospectively while receiving standard treatment. Patients with active bleeding, ongoing ECMO, conditions that make capillary refill time measurement unreliable (e.g., Raynaud phenomenon or significant peripheral vascular disease), death within the first 6 hours, or inability to obtain hour-6 CRT or blood gas measurements are not included.

Descrição

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline
  • Presence of both a central venous catheter and an arterial line

Exclusion Criteria:

  • Active bleeding
  • Ongoing extracorporeal membrane oxygenation (ECMO)
  • Raynaud phenomenon or significant peripheral vascular disease that makes capillary refill time measurement unreliable (e.g., critical ischemia, amputation, digital ulcer/necrosis, or inability to measure on the right index finger)
  • Death within the first 6 hours
  • Inability to obtain hour-6 CRT or blood gas (phenotyping not possible)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
septic schoc cohort
Consecutive adult patients (≥18 years) admitted to the intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who have pre-existing central venous and arterial catheters. Patients are prospectively followed while receiving standard care, with serial measurements at hours 0, 6, 12, and 24 (time zero = vasopressor initiation). At hour 6, patients are classified into perfusion phenotypes based on capillary refill time (CRT) and oxygen extraction ratio (O₂ER): concordant normal, discordant with high O₂ER, discordant with low O₂ER, and concordant abnormal. The primary group of interest is the combined discordant phenotype (normalized CRT with abnormal O₂ER).
Non-invasive, standardized bedside measurement of capillary refill time on the right index finger.
Oxygen extraction ratio calculated as (SaO₂ - ScvO₂)/SaO₂ from routinely obtained arterial and central venous blood gases.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Prevalence of the discordant CRT-O₂ER phenotype
Prazo: At hour 6 of resuscitation (6 hours after vasopressor initiation)
Proportion of patients classified as having a discordant perfusion phenotype (normalized CRT ≤3 s with an abnormal O₂ER, i.e., >30% or <20%; combined Group 2a + Group 2b) at hour 6, reported with 95% confidence interval.
At hour 6 of resuscitation (6 hours after vasopressor initiation)
28-day all-cause mortality
Prazo: 28 days from Hour 0 (vasopressor initiation)
All-cause mortality at 28 days, and its association with the hour-6 perfusion phenotype.
28 days from Hour 0 (vasopressor initiation)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
ICU length of stay
Prazo: Through study completion, up to 28 days
Duration of intensive care unit stay in days.
Through study completion, up to 28 days
Hospital length of stay
Prazo: Through study completion, up to 28 days
Duration of hospital stay in days.
Through study completion, up to 28 days
Duration of mechanical ventilation
Prazo: Through study completion, up to 28 days
Total days on mechanical ventilation (0 if never ventilated).
Through study completion, up to 28 days
Time to vasopressor weaning
Prazo: From Hour 0 up to 28 days
Time in hours to sustained vasopressor discontinuation (off ≥24 continuous hours), measured from Hour 0.
From Hour 0 up to 28 days
Vasopressor-free days
Prazo: 28 days
Number of days alive and free of vasopressor support within 28 days.
28 days
Organ dysfunction at hour 72
Prazo: Hour 72
SOFA-2 score at hour 72, together with ongoing vasopressor/mechanical ventilation status and lactate level.
Hour 72
Need for renal replacement therapy (RRT)
Prazo: Within 28 days
Proportion of patients requiring newly initiated RRT within 28 days (chronic dialysis patients excluded from the "new" category).
Within 28 days

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Diagnostic performance of the O₂ER threshold for mortality
Prazo: Hour 6 measurement; mortality at 28 days
Discriminative ability of O₂ER for 28-day mortality assessed by ROC analysis (area under the curve), with identification of the optimal cut-off and comparison to the literature threshold of 30%.
Hour 6 measurement; mortality at 28 days
Inter-rater reliability of CRT measurement
Prazo: Hour 6, first 20-30 patients
Agreement of hour-6 CRT between two independent, blinded observers; intraclass correlation coefficient (ICC) for continuous values and Cohen's kappa for the ≤3 s normal/abnormal classification.
Hour 6, first 20-30 patients

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

17 de agosto de 2026

Conclusão Primária (Estimado)

17 de junho de 2027

Conclusão do estudo (Estimado)

17 de julho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

15 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de agosto de 2026

Primeira postagem (Real)

19 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever